HK1120273A1 - 抗體及其使用方法 - Google Patents

抗體及其使用方法

Info

Publication number
HK1120273A1
HK1120273A1 HK09100473.7A HK09100473A HK1120273A1 HK 1120273 A1 HK1120273 A1 HK 1120273A1 HK 09100473 A HK09100473 A HK 09100473A HK 1120273 A1 HK1120273 A1 HK 1120273A1
Authority
HK
Hong Kong
Prior art keywords
fgf19
methods
same
antibodies
fgf19 antibodies
Prior art date
Application number
HK09100473.7A
Other languages
English (en)
Inventor
Luc Desnoyers
Dorothy French
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1120273A1 publication Critical patent/HK1120273A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
HK09100473.7A 2006-02-10 2009-01-16 抗體及其使用方法 HK1120273A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77231006P 2006-02-10 2006-02-10
US78060806P 2006-03-09 2006-03-09
US88586607P 2007-01-19 2007-01-19
PCT/US2007/061936 WO2007136893A2 (en) 2006-02-10 2007-02-09 Anti-fgf19 antibodies and methods using same

Publications (1)

Publication Number Publication Date
HK1120273A1 true HK1120273A1 (zh) 2009-03-27

Family

ID=38723925

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09100473.7A HK1120273A1 (zh) 2006-02-10 2009-01-16 抗體及其使用方法

Country Status (11)

Country Link
US (4) US7678373B2 (zh)
EP (1) EP1989230B1 (zh)
JP (1) JP5209505B2 (zh)
AR (1) AR059432A1 (zh)
AU (1) AU2007254005B2 (zh)
CA (1) CA2637988A1 (zh)
ES (1) ES2582652T3 (zh)
HK (1) HK1120273A1 (zh)
NZ (1) NZ569957A (zh)
TW (1) TWI388568B (zh)
WO (1) WO2007136893A2 (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
ATE450615T1 (de) 2005-07-22 2009-12-15 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
TWI388568B (zh) * 2006-02-10 2013-03-11 Genentech Inc 抗ｆｇｆ１９抗體及其使用方法
US20100267145A1 (en) * 2006-06-05 2010-10-21 Hiroshima University Immunocompetent cell having anti-cd38 antibody on its cell surface
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
NO2550972T3 (zh) * 2007-04-02 2018-07-21
US8236307B2 (en) 2007-08-03 2012-08-07 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
US20090226459A1 (en) * 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
RU2010147806A (ru) * 2008-04-30 2012-06-10 Внтрисерч Аб (Se) Восстановление активности a-рецептора эстрогена
SG191679A1 (en) 2008-06-16 2013-07-31 Immunogen Inc Novel synergistic effects
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
RU2509774C2 (ru) 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
MX368790B (es) * 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
CA2780457A1 (en) 2009-11-13 2011-05-19 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
JP4881428B2 (ja) * 2009-12-25 2012-02-22 株式会社東芝 電子機器
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2683736B1 (en) 2011-03-09 2018-01-17 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
EP2723391B1 (en) * 2011-06-24 2018-06-13 University of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
JP2015505818A (ja) 2011-11-14 2015-02-26 ファイブ プライム セラピューティックス インコーポレイテッド 癌を治療する方法
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
EP2804630B1 (en) * 2012-01-18 2017-10-18 F. Hoffmann-La Roche AG Methods of using fgf19 modulators
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US10793626B2 (en) * 2013-12-20 2020-10-06 Angiobiomed Gmbh Adrenomedullin binder for use in therapy of cancer
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
PL3200786T3 (pl) 2014-10-03 2020-03-31 Novartis Ag Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4
AU2015335844B2 (en) * 2014-10-23 2020-09-03 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016151499A1 (en) 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
EP3414267B1 (en) * 2016-02-10 2023-12-27 BioInvent International AB Combination of human anti-fgfr4 antibody and sorafenib
EP3453392A4 (en) * 2016-05-17 2020-03-04 Japanese Foundation For Cancer Research THERAPEUTIC FOR LUNG CANCER THAT HAS OBTAINED EGFR-TKI RESISTANCE
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
JP7394623B2 (ja) 2016-11-02 2023-12-08 ノバルティス アーゲー Ｆｇｆｒ４インヒビターおよび胆汁酸捕捉薬の組合せ
CN109251983B (zh) * 2018-08-15 2022-03-25 深圳市罗湖区人民医院 Frs2基因的拷贝数扩增及其应用、检测拷贝数扩增的特异性引物对
CN113710701A (zh) * 2019-02-02 2021-11-26 华辉安健（北京）生物科技有限公司 抗fgf19抗体
PL3865155T3 (pl) * 2020-02-13 2023-01-30 Orano Med Sposób miejscowo-specyficznego modyfikowania przeciwciała
WO2023225334A1 (en) 2022-05-19 2023-11-23 Tyra Biosciences, Inc. Therapies with ppar agonists and fgfr4 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US20020012961A1 (en) * 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
US20020042367A1 (en) * 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20040126852A1 (en) * 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US20020155543A1 (en) * 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
CA2309783C (en) 1997-11-25 2011-06-28 Genentech, Inc. Fibroblast growth factor-19
US20050026832A1 (en) * 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
ES2264929T3 (es) 1999-09-08 2007-02-01 Genentech, Inc. Acidos nucleicos y polipeptidos del factor 19 de crecimiento fibroblastico (fgf-19) y procedimientos de utilizacion para el tratamiento de la obesidad.
US7348162B2 (en) 2000-03-22 2008-03-25 Amgen Inc. Nucleic acids encoding fibroblast growth factor receptor-like proteins and uses thereof
EP1353947A2 (en) 2000-12-08 2003-10-22 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
JP2005518782A (ja) 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
WO2003065006A2 (en) 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
AU2003243400B2 (en) * 2002-06-07 2009-10-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050198642A1 (en) * 2004-03-04 2005-09-08 International Business Machines Corporation Mechanism for assigning home nodes to newly created threads
US7837626B2 (en) * 2005-08-05 2010-11-23 Siemens Medical Solutions Usa, Inc. Contrast agent manipulation with medical ultrasound imaging
TWI388568B (zh) 2006-02-10 2013-03-11 Genentech Inc 抗ｆｇｆ１９抗體及其使用方法

Also Published As

Publication number Publication date
NZ569957A (en) 2012-03-30
US20110086032A1 (en) 2011-04-14
AR059432A1 (es) 2008-04-09
US20100129381A1 (en) 2010-05-27
US20070248604A1 (en) 2007-10-25
AU2007254005B2 (en) 2012-11-29
JP5209505B2 (ja) 2013-06-12
US7678373B2 (en) 2010-03-16
EP1989230A2 (en) 2008-11-12
AU2007254005A1 (en) 2007-11-29
US7846691B2 (en) 2010-12-07
CA2637988A1 (en) 2007-11-29
EP1989230B1 (en) 2016-06-01
TWI388568B (zh) 2013-03-11
WO2007136893A2 (en) 2007-11-29
US8293241B2 (en) 2012-10-23
TW200808827A (en) 2008-02-16
JP2009525764A (ja) 2009-07-16
US8241633B2 (en) 2012-08-14
US20120128675A1 (en) 2012-05-24
WO2007136893A3 (en) 2008-05-15
ES2582652T3 (es) 2016-09-14

Similar Documents

Publication Publication Date Title
HK1120273A1 (zh) 抗體及其使用方法
IL192419A0 (en) Anti-ephb4 antibodies and methods using same
IL194787A0 (en) Anti-dll4 antibodies and methods using same
IL240245A0 (en) Antibodies against 5t4 and their uses
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
ZA200804868B (en) Anti-OX40L antibodies and methods using same
HK1194395A1 (zh) 抗體及其製備和使用方法
IL196397A0 (en) Prlr-specific antibody and uses thereof
IL222922A (en) Antibodies against neurophilin-1 and their use
ZA200900395B (en) Antibodies directed to +-Vß6 and uses thereof
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
EP2094307A4 (en) TES7 AND THEREO BINDING ANTIBODIES
IL184024A0 (en) Irta-5 antibodies and their uses
IL231891A (en) Anti-ephrinb2 antibodies and methods for their use
ZA200809100B (en) Anti-DLL4 antibodies and methods using same
ZA200806053B (en) Anti-EphB4 antibodies and methods using same
EP1996938A4 (en) IMMOBILIZED PROTEINS AND USE METHOD THEREFOR
GB0610059D0 (en) Uses and methods
GB0621272D0 (en) Assay and method
AU2006903659A0 (en) Antibodies and related methods
ZA200705716B (en) IRTA-2 antibodies and their uses
GB0606794D0 (en) Methods and uses
GB0611806D0 (en) Materials and methods

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210209